LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
45.33
-0.52 (-1.13%)
Aug 11, 2026, 4:00 PM EDT - Market closed

LB Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Income
-95.14-30.4-64.83-11.38-2.81
Net Income
-85.69-25.21-63.1-6.28-14.35
Earnings Per Share
-3.44-3.13-176.15-21.86-62.19
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
327.79295.212843.2921.4
Total Debt
5.223.573.7024.15
Net Cash (Debt)
322.57291.6424.343.29-2.74
Net Cash Growth
2982.69%1100.38%-43.88%--
Net Cash Per Share
14.4036.2567.82150.75-11.87

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-82.4-35.21-53.05-12.09-2.73
Capital Expenditures
-0.44-0.05-0.77-0.03-
Free Cash Flow
-82.83-35.26-53.82-12.12-2.73
Free Cash Flow Growth
-----

Valuation

Selected indicators aren't available for this stock.